Adjuvant chemotherapy

Where the papers sit

10 papers from the last 6 months study adjuvant chemotherapy directly · updated from PubMed 3 Nov 2026

• Gastrointestinal Adjuvant Treatment

  Adjuvant treatment decisions in gastrointestinal cancer are being shaped by stage, postoperative fitness and the likelihood of completing chemotherapy. Gastric and rectal cancer analyses assess survival benefit using hazard ratios and disease-free survival, including T3N0 disease and FOLFIRINOX-based total neoadjuvant therapy. Frailty screening with G8 and lymphocyte counts highlights early discontinuation after complications, especially in older adults. The unresolved question is how to preserve oncological benefit while limiting treatment burden.

  4 papers · 40%

• Genomic Selection in Breast Cancer

  Treatment selection is increasingly combining genomic risk with clinicopathological features in early breast cancer. The 21-gene recurrence score is used to refine chemotherapy decisions, while small node-negative triple-negative tumours remain a question of absolute benefit. Patient-reported outcomes recur through QLQ-C30 symptoms and functional impairment during treatment. The field is balancing recurrence reduction against toxicity and quality of life.

  3 papers · 30%

• Multimodality Therapy in Gastrointestinal Cancer

  Multimodality treatment is being tested by comparing chemoradiotherapy alone with regimens that add adjuvant chemotherapy across gastrointestinal cancers. Outcomes centre on overall and disease-free survival, mortality and treatment benefit in stage III or resected disease. The lymph node ratio is used to stratify individualized benefit in gastric cancer, while pancreatic trials examine the contribution of radiotherapy after chemotherapy. Results remain disease-specific, leaving the optimal sequencing and selection of patients for combined treatment open.

  3 papers · 30%